No profile data available.
Incyte Corporation (INCY) is a healthcare company in the blood disorder treatment drugs industry, based in Wilmington, United States, with about 2,844 full-time employees.
It reported revenue of $5.14 billion for fiscal year 2025, up 21.2% from fiscal year 2024, and net income of $1.29 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.67 billion, up 37.7% from a year before. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $22.86 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Incyte reported $5.14 billion in revenue for fiscal year 2025, up 21.2% from $4.24 billion in fiscal year 2024. In Q2 2026 revenue was $1.67 billion.
United States: 93% of revenue by region in fiscal year 2025, followed by Europe (6%).
$22.86 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Protagonist Therapeutics, Inc. (PTGX), Agios Pharmaceuticals, Inc. (AGIO), uniQure N.v. (QURE), Ultragenyx Pharmaceutical Inc. (RARE).